As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Elon Musk's brain-computer interface startup Neuralink secured $650 million in series E funding to expand patient access to ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

Protein degradation company Plexium has laid off staff as part of a realignment to support the company’s pipeline, which is ...

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) inhibitor to have made it into the clinic.

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

OSE Immunotherapeutics has shared survival data behind a therapeutic vaccine’s phase 2 pancreatic cancer win as the French ...

Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell ...